Escalating Dose Study for Safety, Tolerability and Pharmacokinetics After Single and Multiple Dermal Administration of Two BAY1003803 Formulation Types With Two Concentrations Each in Healthy Male Volunteers, Applying a Double-blind, Vehicle-controlled Design and Including a Positive Control Group
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2017
At a glance
- Drugs BAY 1003803 (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- Sponsors Bayer
- 10 Aug 2017 Planned End Date changed from 15 Oct 2017 to 1 Sep 2017.
- 19 May 2017 Status changed from recruiting to active, no longer recruiting.
- 16 Mar 2017 Planned End Date changed from 1 Oct 2017 to 15 Oct 2017.